resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5521
Debt
Debt-to-Equity RatioN/A
Current Ratio20.03
Quick Ratio20.04
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.17) per share
Price / Book-7.68
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares28,050,000
Market Cap$256.62
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio, Inc. (NASDAQ:TORC) released its earnings results on Thursday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.20. View resTORbio's Earnings History.
What price target have analysts set for TORC?
4 Wall Street analysts have issued 1 year price targets for resTORbio's shares. Their predictions range from $23.00 to $36.00. On average, they anticipate resTORbio's stock price to reach $29.25 in the next twelve months. This suggests a possible upside of 225.0% from the stock's current price. View Analyst Ratings for resTORbio.
What is the consensus analysts' recommendation for resTORbio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include Flexion Therapeutics (FLXN), Omeros (OMER), Dynavax Technologies (DVAX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), Epizyme (EPZM), CytomX Therapeutics (CTMX), Amarin (AMRN), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX), Inflarx (IFRX), AC Immune (ACIU) and Kiniksa Pharmaceuticals (KNSA).
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)
- Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 50)
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68)
- Ms. Susan Stewart J.D., Head of Regulatory Affairs
When did resTORbio IPO?
(TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does resTORbio's lock-up period expire?
resTORbio's lock-up period expires on Wednesday, July 25th. resTORbio had issued 5,666,667 shares in its initial public offering on January 26th. The total size of the offering was $85,000,005 based on an initial share price of $15.00. After the expiration of resTORbio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Has resTORbio been receiving favorable news coverage?
Media coverage about TORC stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. resTORbio earned a media sentiment score of 0.22 on Accern's scale. They also gave news headlines about the company an impact score of 46.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $9.00.
How big of a company is resTORbio?
resTORbio has a market capitalization of $256.62 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe.
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (NASDAQ TORC)
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
